Article ; Online: Bevacizumab: Is the lower the better for glioblastoma patients in progression?
2018 Volume 105, Issue 12, Page(s) 1135–1146
Abstract: Introduction: Based on the radiological responses obtained with a schedule of ten mg/kg every two weeks bevacizumab was approved by the FDA for recurrent glioblastomas. Due to the negative results concerning overall survival of patients receiving ... ...
| Abstract | Introduction: Based on the radiological responses obtained with a schedule of ten mg/kg every two weeks bevacizumab was approved by the FDA for recurrent glioblastomas. Due to the negative results concerning overall survival of patients receiving bevacizumab, the European application was rejected. Despite this, many centers apply an off-label prescription. Our aim was to evaluate the safety and efficacy of schedules of low doses of bevacizumab. Methods: From September 2013 to August 2016, we recruited patients with progressive glioblastoma, whatever the previous treatments. We compared a routine control group (CG) of ten mg/kg, to a low dose group (LDG) composed of 5 subgroups: G5: five mg/kg, G4: four mg/kg, G3: three mg/kg, G2: two mg/kg, G1: one mg/kg; each patient was treated with the same dose every two weeks. Results: Fifty-three patients were treated: 20 women and 33 men, 24 in the CG and 29 in the LDG. The median age at diagnosis was 62 years [35.0-77.0]. No statistical difference was found in overall survival either for the CG or the LDG (P=0.086) or among groups (P=0.251), with even a trend toward improvement for LDG: 62 weeks [20-145] versus 73 weeks [18-178]. The median progression free survival was comparable: 19.5 weeks [6.0-54.0] for the CG and 15.0 weeks [0.0-134.0] for the LDG (P=0.221). Bevacizumab was stopped either due to progression (45.1%) or toxicity (52.9%), without significant differences between doses but maybe less toxicities in the LDG (16.7% for toxicity in G1). Discussion: Use of bevacizumab at progression at lower than usual doses seems to give the same results as the standard dose without giving additional toxicity. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Brain Neoplasms/drug therapy ; Drug Dosage Calculations ; Female ; Glioblastoma/drug therapy ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Progression-Free Survival ; Prospective Studies |
| Chemical Substances | Antineoplastic Agents, Immunological ; Bevacizumab (2S9ZZM9Q9V) |
| Language | English |
| Publishing date | 2018-10-06 |
| Publishing country | France |
| Document type | Journal Article ; Multicenter Study |
| ZDB-ID | 213270-9 |
| ISSN | 1769-6917 ; 0007-4551 |
| ISSN (online) | 1769-6917 |
| ISSN | 0007-4551 |
| DOI | 10.1016/j.bulcan.2018.07.010 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.15: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.